Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.

ABSTRACT:

Background

Alcohol use disorder (AUD) remains a major public health problem, with few effective medications currently available. However, peptides of the gut-brain axis appear to offer promising therapeutic targets for AUD as they influence the mesolimbic reward circuitry.

Methods

Here, we examined the effects of tirzepatide, a long-acting dual glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist approved for diabetes and obesity, using behavioural assays (locomotor activity and conditioned place preference), alcohol intake paradigms (intermittent access two-bottle choice, drinking in the dark and the alcohol deprivation effect), and molecular analyses (microdialysis, electrophysiology and proteomics) in rodents.<

SUBMITTER: Edvardsson CE 

PROVIDER: S-EPMC12808897 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature